3 Reasons to Shift from Weight Management to Weight Health in the GLP-1 Era

February 24th, 2026

Authored by: Ashley Koff, RDN, IFNA faculty

3 Reasons to Shift from Weight Management to Weight Health in the GLP-1 Era

The GLP-1 era has reshaped conversations about obesity and diabetes. But for those of us who practice whole-person care, this new era invites a huge opportunity: to transition patients and care from a weight loss, weight management approach to a weight health one. And that will bring so many more wins with patient empowerment topping the list. What we know to be true and problematic:

 

  • Weight management frames it as an issue, a patient’s issue, not involving their practitioner, and one in which they need to learn to manage it themselves.
  • Weight loss focuses on reducing a total number. A number we know to be meaningless when it comes to their health.
  • Patients can lose weight without finding health. Worse, weight loss efforts can worsen health challenge by further limiting resources available and now with biosimilar hormone replacement therapy – they can challenge the body’s weight-health ecosystem operations.
  • Diet and exercise, while valuable tools, are the exclusive tools of weight management. Now adding a GLP-1 agonist. But we have a more expansive toolkit to personalize and optimize their weight health.

Weight health repositions the type and role of weight – from a singular number to a set of numbers (body composition – fat, muscle, bone and water), their type and location, not just the amount- as one key signal to decode.

I wrote Your Best Shot to ensure that whether someone uses a GLP-1 agonist or not, they are not simply losing weight, but gaining metabolic health, or what I call weight health. Because the goal is not weight reduction alone. It is physiologic optimization.

That distinction matters for optimization – today and tomorrow.

Here are three reasons practitioners should consider the shift.

  1. Weight Loss Alone Does Not Guarantee Improved Health

Body weight is at best an imperfect proxy for health. The commonly used body mass index (BMI) does not distinguish between fat mass and lean mass, nor does it assess fat distribution or metabolic function.

Research consistently shows that visceral adiposity, not total weight alone, is more strongly associated with cardiometabolic risk, insulin resistance, and cardiovascular disease (Després, 2012; Powell-Wiley et al., 2021).

When weight loss occurs without attention to muscle preservation, optimal nutrient levels, inflammation, and hormonal signaling, clinical outcomes may not improve proportionally.

In Your Best Shot, I outline weight health as a clinical framework that prioritizes body composition, metabolic flexibility, and systemic function rather than pursuing scale reduction as the endpoint.

Body composition provides more meaningful insight than total weight. Preservation of lean mass, reduction of visceral fat, and maintenance of hydration status are all associated with improved metabolic and cardiovascular outcomes.

Loss of muscle mass during weight reduction can negatively impact metabolic rate and long-term health trajectories. Muscle loss is particularly relevant in aging populations and in patients using GLP-1 therapies, where appetite suppression may reduce overall protein intake.

Emerging evidence links metabolic health, muscle mass, and cardiovascular outcomes in ways that cannot be captured by BMI alone (Blüher, 2019).

Weight health integrates:

  • Body composition
  • Digestive function
  • Hormonal signaling
  • Inflammation
  • Hydration and electrolyte balance
  • Metabolic markers

This systems approach aligns more closely with physiologic regulation than weight-centric models.

  1. Weight-Health Hormones Require Digestive Integrity

GLP-1, GIP, PYY, and CCK are gut-derived hormones that regulate appetite, satiety, glucose homeostasis, fat distribution, bone formation, and aspects of inflammation and vascular function.

These hormones are produced by enteroendocrine cells in the gastrointestinal tract and are activated by nutrient exposure and digestion.

Optimal signaling depends on:

  • Adequate protein breakdown into amino acids
  • Efficient fat digestion into absorbable fatty acids
  • Fiber availability and diversity
  • Sufficient micronutrient availability
  • Movement of nutrients to their destinations for use and waste products for elimination

Digestive efficiency, therefore, plays a foundational role in weight-health hormone function.

GLP-1 receptor agonists further underscore this connection. These medications alter gastric emptying and appetite signaling (Drucker, 2018). As a result, patients may experience changes in food tolerance and digestive patterns. Supporting digestion alongside pharmacotherapy may improve nutrient delivery and tolerability.

Additionally, digestive enzymes are part of the digestive efforts for breaking down food; they are not optional supplementation. They facilitate the breakdown of macronutrients into bioavailable components. Age, stress, inflammation, medication use, and gastrointestinal conditions can reduce endogenous enzymatic activity, potentially impairing nutrient absorption. If we lack them, digestion and weight health will suffer. We may supplement or use strategies to cultivate endogenous ones more effectively – or both.

As we all know, from a systems perspective, digestion is not separate from metabolic regulation. It is upstream of it. Thus, it is the “crust” or foundation of every person’s weight health optimization plan.

  1. Inflammation Is a Signal That Requires Optimization, Not Just Suppression

Inflammation is often treated as something to reduce or block. In reality, chronic low-grade inflammation is frequently a reflection of unmet physiologic needs.

Visceral adiposity, glycemic variability, micronutrient insufficiency, impaired digestion, dehydration, and stress physiology all contribute to inflammatory burden.

Resolving inflammation requires:

  • Essential fatty acids, enough for prevention and resolution phases
  • Enzymes for conversion into resolvins
  • Micronutrients
  • Efficient digestion and absorption

GLP-1 receptor agonists have demonstrated anti-inflammatory effects beyond glycemic control, including improvements in endothelial function and reductions in inflammatory markers (Drucker, 2018; Nauck et al., 2021). Emerging evidence suggests these benefits may occur even at lower doses and may not depend entirely on the magnitude of fat loss.

This reinforces an important clinical point: weight reduction alone does not resolve inflammation. Optimized physiology does.

When inflammation is viewed as a measurable, modifiable component of weight health, practitioners move from chasing weight change to restoring systemic integrity.

The Clinical Opportunity

GLP-1 medications are not a replacement for physiology. They are tools that operate within it.

In the IFNA program you now have access to my training on how and why to implement the weight health approach.

If interested in a consumer-facing approach to it, you can read more here and get our free download.

Weight health does not discard fat reduction when appropriate. Instead, it reframes weight composition changes as one outcome of ecosystem optimization.

The goal is not smaller bodies or even a lower rate of obesity; it’s better-functioning bodies, it’s moving the needle on the statistic that 9 in 10 American adults do not meet the criteria for metabolic health.

Want to learn more about Weight and Metabolic Health at the IFN Academy? Register here today!

References

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298. doi:10.1038/s41574-019-0176-8 https://pubmed.ncbi.nlm.nih.gov/30814686/

Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301-1313. doi:10.1161/CIRCULATIONAHA.111.067264. https://pubmed.ncbi.nlm.nih.gov/22949540/

Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. https://pubmed.ncbi.nlm.nih.gov/29617641/Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001

https://pubmed.ncbi.nlm.nih.gov/29617641/

Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi:10.1161/CIR.000000000000097.
https://pubmed.ncbi.nlm.nih.gov/33882682/